Search clinical trials for: 1% icotinib hydrochloride cream

Total 1067 results

Novartis Pharmaceuticals

Completed

Impact of Fingolimod Adherence on Outcomes

Multiple Sclerosis

United States
National Cancer Institute (NCI)

Not yet recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
Novartis

Completed

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Relapsing Multiple Sclerosis

Germany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (Biobank)

Relapsing-remitting Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Colombia, Panama, Peru, Brazil, Jordan, Malaysia, Mexico, Argentina
Jochen Vehoff

Completed

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (ANSG)

Multiple Sclerosis | Autonomic Nervous System Dysfunction

Switzerland
Pfizer

Completed

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

Healthy | Type 2 Diabetes Mellitus

United States
Galderma R&D

Completed

Oracea Soolantra Association in Participants With Severe Rosacea (ANSWER)

Rosacea

United States, Canada, Hungary
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Stanford University

Withdrawn

Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion

Pain

United States
Ain Shams Maternity Hospital
Ain Shams University

Unknown

Lidocaine-Prilocaine Cream (EMLA) Topical Application Versus Wound Infiltration With Lidocaine After Cesarean Section

Post Operative Pain

Egypt
Thomas Jefferson University
Verastem, Inc.

Active, not recruiting

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Novartis Pharmaceuticals

Completed

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

Germany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
Novartis Pharmaceuticals

Completed

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (PASSOS)

Relapsing Remitting Multiple Sclerosis RRMS

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Fingolimod -Response According to Coping - Evaluation (GRACE)

Multiple Sclerosis, Relapsing-Remitting

France
Novartis

Completed

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

Multiple Sclerosis

United States, Canada
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Multiple Sclerosis

Japan
Novartis

Completed

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

Healthy

United States
Tianjin Medical University General Hospital

Completed

Efficacy and Safety of FTY720 for Acute Stroke

Stroke | Stroke, Acute | Cerebral Stroke | Ischemic Cerebrovascular Accident | Vascular Accident

China
University of Southern California

Completed

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Kidney Transplantation

United States
Novartis Pharmaceuticals

Terminated

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (TOFIINGO)

Relapsing Remitting Multiple Sclerosis (RRMS)

Germany, Spain, Australia, Israel, Switzerland, Italy, Austria, Greece, Hungary, Czech Republic, Finland
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
Teva Pharmaceuticals USA

Completed

Granisetron 1 mg Tablets, Non-fasting

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Granisetron 1 mg Tablets Under Fasting Conditions

Healthy

Canada
Novartis Pharmaceuticals

Recruiting

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis (SPRING)

Multiple Sclerosis

Taiwan
Novartis

Completed

Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.

Renal Insufficiency

Russian Federation
Novartis Pharmaceuticals

Completed

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Relapsing-remitting Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
Novartis Pharmaceuticals

Completed

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Kidney Transplantation
Heinrich-Heine University, Duesseldorf
Novartis Pharmaceuticals

Terminated

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (BiobankII)

Relapsing Remitting Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Completed

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Multiple Sclerosis | Relapsing-Remitting

Turkey
Pfizer

Completed

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan
Children's Hospital Medical Center, Cincinnati

Withdrawn

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

Pain

United States
Shanghai Jiao Tong University School of Medicine

Unknown

A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes

Type 2 Diabetes

China
Chemische Fabrik Kreussler & CO GmbH
Anfomed GmbH

Completed

Acceptance and Preference of Lidocaine Gel Compared to Injection Anesthesia After Non Surgical Periodontal Treatment

Periodontitis

Germany
Shanghai Mental Health Center

Unknown

Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression

Depressive Disorder

China
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
Translational Oncology Research International
National Cancer Institute (NCI)

Completed

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-2

United States
Kocatepe University

Completed

The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

Benign Prostatic Hyperplasia | Choroid Disease | Pupil Anomaly
First Affiliated Hospital of Fujian Medical University

Withdrawn

Fingolimod in COVID-19

Coronavirus Disease (COVID-19)

China
Novartis Pharmaceuticals

Completed

Fingolimod Effect on Cytokine and Chemokine Levels

Relapsing Remitting Multiple Sclerosis

Turkey
Novartis Pharmaceuticals

Terminated

Effect of Fingolimod on Neurodegeneration

Cognition | Brain Volume Loss

Turkey
Massachusetts General Hospital
ALS Therapy Development Institute

Completed

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Ning Wang, MD., PhD.

Recruiting

Fingolimod in Endovascular Treatment of Ischemic Stroke

Stroke Inflammation

China
Novartis

Completed

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

Asthma

United Kingdom
Novartis Pharmaceuticals

Completed

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Multiple Sclerosis

Italy, Belgium, Germany
Novartis

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Switzerland, Germany, Spain, Portugal, Canada, Denmark, Finland, France, Italy, Poland, United Kingdom

Search clinical trials for: 1% icotinib hydrochloride cream

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations